FDA announces recall of more than 32 million disposable syringes

Cardinal Health is recalling more than 32 million disposable syringes, according to a new alert from the U.S. Food and Drug Administration (FDA). This is a Class I recall, which means the FDA believes using these products “may cause serious injuries or death.”

The company first started distributing its Cardinal Health Monoject syringes in June 2023. Compared to the Covidien Monoject syringes, however, these newer products were designed with different dimensions that are causing ongoing issues with syringe pumps. According to the FDA, these different dimensions “may result in pump performance issues such as overdose, underdose, delay in therapy, and delays in occlusion alarms.”

Cardinal Health recalled syringes

As pictured above, the Covidien Monoject syringe on the left has different dimensions than the Cardinal Health Monoject syringe on the right. Image and caption courtesy of the FDA.

The recall includes a total of 32.43 million disposable syringes distributed from June to August 2023. A full list of product names and product codes is available on the FDA’s advisory.

Cardinal Health has received 15 reports of therapy being delayed due to this issue. There have been another 13 reports of inaccurate volume/rate dispensing.

The FDA emphasized that this is not necessarily a correction, it is a warning that the Cardinal Health Monoject syringes should not be used with syringe infusion pumps.

The Covidien-branded Monoject syringes can still be used with syringe infusion pumps if customers still have those on hand.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Trimed Popup
Trimed Popup